Senping Cheng
成森平
Senping Cheng is the founder and CEO of Triastek (三迭纪), a pharmaceutical company applying 3D printing technology to drug development . She established the firm together with co-founder and chief scientific officer Professor Li Xiaoling, with the idea originating from a conversation between the two . Under her leadership, Triastek has advanced multiple 3D-printed drug candidates into clinical trials, including a 2022 FDA IND approval for T21, a lower-dose treatment for ulcerative colitis , and has partnered with Boehringer Ingelheim to explore the application of its MED® 3D printing platform in new drug R&D . Cheng was named to Forbes China's "2023 Businesswomen to Watch" list .
AI-generated — may contain errors, please verify.
Coverage
Triastek, an Early Yunqi Capital Portfolio Company, Closes New Strategic Funding Round, Launching New Oral Peptide Strategy | Yunqi Capital
Bringing Innovation to Patients, Faster
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Yunqi Capital's Back-to-Work Special: 2025 — Talking Confidence with Tech Founders and Partners
The Lunar New Year holiday just past was anything but quiet in the global tech world. DeepSeek — that "mysterious force from the East" — shattered the assumption that top-tier AI performance requires top-tier computing power, reshaping the global AI landscape through a series of technical innovations and planting a seed of confidence for the year of innovation ahead.
Rooted in Reality, Driven by Innovation, Moving Forward Without Pause | Dalton Venture's 2024 Annual Partners Meeting Successfully Concludes
Pressing forward into the real, advancing toward the new — the resolve to push ahead undimmed.
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
How Can a "3D Printer" Boost Productivity in the Pharmaceutical Industry? | The B-Side of Entrepreneurship
Take the hard, meaningful path
Spring Tide Surges, A Thousand Sails Compete — Dalton Venture Annual CEO Summit | Tong Learning Society
Gather friends, gather energy, gather spirit
"Triastek" Partners with World's Largest Private Pharmaceutical Company: 3D Printing Technology Accelerates New Drug R&D | Yunqi Tech π
Triastek Enters Partnership with Boehringer Ingelheim
MaKe | Four MaHui Member Company Executives Named to Forbes China's "2023 Businesswomen to Watch" List
Businesswomen are working new wonders for China's economy
What Are We Actually Reviewing When We Talk About "Reviewing"? | Yunjian · Zhengyuan
After the "Cloud Sight" Series Concludes
Two FDA INDs Approved in Two Years: Triastek's Third 3D-Printed Drug Enters Clinical Trials | Yunqi Capital
Enhanced Safety Through Precision Drug Targeting and Delivery
